Saturday, November 11, 2017 8:51:58 AM
The company needs to get back to its original business model. which is designing hard to make medications then partner them out for either profit sharing and or licensing out the technology.
Under this model you get the best of both worlds. Odidi is a brilliant scientist. Your overhead is negligible,needing only labs and low amount of workers. As soon as you obtain the approvals the partnerships start bringing in revenue, which is self sustaining of the modest operations and gives you a chance to move onto your next invention.
The reason this business model failed is Odidi. once he invented the technology he is unwilling to follow through with the next step which is partner it out. I personally think ts a bad taste left in him with Biovail, where they used him and he got got nothing in return yet he made the rest rich. Now he is afraid by partnering they will steal his technology. all of a sudden, instead of partnering his inventions he started changing gears and thought he could manufacturer himself. why? because he doesn't trust anyone with the technology! while this may work with the generics, it will never work with Rexista, Regabatin and now even Podras technology. which is why we haven't seen any partnerships!
we need to get Odidi to realize we will never be a major pharmaceutical. we could be a huge technology giant however! He needs to secure his patents, develop the drugs and then partner. from that point on, rely on the legal system to take to court any company, which steal his technology.
Regabatin has been sitting idle for 2 years waiting on a partner. Rexista, with what they filed, could have been filed 2 years ago! Podras only needs to be proven in animals and it could be licensed out for hundreds of other drugs to start NDA supplements ! partnerships with those 3 would generate at least 50 million up front giving more than enough money to allow Odidi to sit in the comfort of his lab to develop the next Podras! and then the upcoming royalties and future milestone payments even more!
we certainly do not need to be adding to overhead to try and go it alone in the generic market. All the man needs to do is get back to his original business model!
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM
VOCODIA HOLDINGS INC. (OTCMKTS: VHAI) and TRACCOM INC. (OTCMKTS: TRCC) have signed an MOU to form a Joint Venture that will Revolutionize Event Monitoring with Narrative AI • VHAI • Jan 15, 2025 2:53 PM
UAV Corp (OTC: UMAV) Engages Legal Counsel to Initiate Uplisting Process with Ultimate Goal of NASDAQ Listing • UMAV • Jan 15, 2025 8:30 AM
HealthLynked Welcomes Jeremy Daniel as Chief Financial Officer • HLYK • Jan 15, 2025 8:00 AM
Zefiro Methane Corp. Subsidiary Awarded Slate of Government of Ohio-Funded Environmental Remediation Projects • ZEFI • Jan 15, 2025 7:33 AM